×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AKBA – akebia therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AKBA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/7
08:02 am
akba
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
Low
Report
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
4/7
08:00 am
akba
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
Low
Report
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
4/6
03:32 am
akba
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates [Yahoo! Finance]
Medium
Report
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates [Yahoo! Finance]
4/2
04:56 pm
akba
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript [Seeking Alpha]
Medium
Report
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript [Seeking Alpha]
4/2
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2
12:20 pm
akba
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets [Yahoo! Finance]
Low
Report
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets [Yahoo! Finance]
4/1
04:05 pm
akba
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
Low
Report
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
3/31
03:45 am
akba
Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy [Yahoo! Finance]
Medium
Report
Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
07:00 am
AKBA
akebia therapeutics, inc.
IN-LINE
Report
-13.5%
akebia therapeutics, inc.
8/7/2025
07:00 am
AKBA
akebia therapeutics, inc.
BEAT
Report
-23.8%
akebia therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/3
04:07 pm
akba
Form 4 Akebia Therapeutics, For: Apr 01 Filed by: Vickers Philip J.
Medium
Report
Form 4 Akebia Therapeutics, For: Apr 01 Filed by: Vickers Philip J.
4/3
04:06 pm
akba
Form 3 Akebia Therapeutics, For: Apr 01 Filed by: Vickers Philip J.
Medium
Report
Form 3 Akebia Therapeutics, For: Apr 01 Filed by: Vickers Philip J.
4/1
04:48 pm
akba
Form 8-K Akebia Therapeutics, For: Mar 27
Medium
Report
Form 8-K Akebia Therapeutics, For: Mar 27
3/26
03:25 pm
akba
Form SCHEDULE 13G/A Akebia Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Akebia Therapeutics, Filed by: VANGUARD GROUP INC
3/5
06:56 pm
akba
Form 4 Akebia Therapeutics, For: Mar 04 Filed by: Butler John P.
Medium
Report
Form 4 Akebia Therapeutics, For: Mar 04 Filed by: Butler John P.
2/26
07:35 am
akba
Form 10-K Akebia Therapeutics, For: Dec 31
Low
Report
Form 10-K Akebia Therapeutics, For: Dec 31
2/26
07:05 am
akba
Form 8-K Akebia Therapeutics, For: Feb 26
Medium
Report
Form 8-K Akebia Therapeutics, For: Feb 26
2/9
06:16 am
akba
Form SCHEDULE 13G Akebia Therapeutics, Filed by: STATE STREET CORP
Medium
Report
Form SCHEDULE 13G Akebia Therapeutics, Filed by: STATE STREET CORP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $15.00 price target on the stock.
34.5%
11/22 Form 4 Akebia Therapeutics, For: Nov 20 Filed by: Smith Cynthia 21.7%
3/23 Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 16.2%
8/8 Q2/2019 6/30/2019 EPS -0.490 ZacksConsensus -0.350 ActVsEst (0.140) - Miss 13.9%
3/13 Akebia Therapeutics, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates [Yahoo! Finance News] 13.2%
3/10 Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 8.2%
3/23 Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference 6.7%
8/8 Form 10-Q Akebia Therapeutics, For: Jun 30 5.8%
4/23 Form DEF 14A Akebia Therapeutics, For: Jun 05 5.3%
9/9 Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock. 5.2%
11/22 Form 4 Akebia Therapeutics, For: Nov 20 Filed by: Smith Cynthia 21.7%
3/23 Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 16.2%
8/8 Q2/2019 6/30/2019 EPS -0.490 ZacksConsensus -0.350 ActVsEst (0.140) - Miss 13.9%
3/13 Akebia Therapeutics, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates [Yahoo! Finance News] 13.2%
3/10 Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 8.2%
3/23 Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference 6.7%
8/8 Form 10-Q Akebia Therapeutics, For: Jun 30 5.8%
4/23 Form DEF 14A Akebia Therapeutics, For: Jun 05 5.3%
9/9 Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock. 5.2%
TOP News Decliners
3/15
A Message from Akebia Therapeutics, Inc.’s Chief Executive Officer to Our Patients, Healthcare Providers, and Other Stakeholders During the Rapidly Evolving COVID-19 Pandemic:
-14.5%
11/12 Q3/2019 9/30/2019 EPS -0.460 ZacksConsensus -0.370 ActVsEst (0.090) - Miss -14.4%
12/2 Introducing Akebia Therapeutics (NASDAQ:AKBA), The Stock That Slid 52% In The Last Five Years [Yahoo! Finance News] -14.1%
3/18 Form SEC STAFF LETTER Akebia Therapeutics, -13.1%
11/9 Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease -9.9%
8/2 Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -8.0%
6/4 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -7.6%
3/10 Q4/2019 12/31/2019 EPS -0.790 ZacksConsensus -0.440 ActVsEst (0.350) - Miss -7.6%
8/2 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.8%
3/11 Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $15.00 price target on the stock, down previously from $16.00. -6.6%
11/12 Q3/2019 9/30/2019 EPS -0.460 ZacksConsensus -0.370 ActVsEst (0.090) - Miss -14.4%
12/2 Introducing Akebia Therapeutics (NASDAQ:AKBA), The Stock That Slid 52% In The Last Five Years [Yahoo! Finance News] -14.1%
3/18 Form SEC STAFF LETTER Akebia Therapeutics, -13.1%
11/9 Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease -9.9%
8/2 Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -8.0%
6/4 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -7.6%
3/10 Q4/2019 12/31/2019 EPS -0.790 ZacksConsensus -0.440 ActVsEst (0.350) - Miss -7.6%
8/2 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.8%
3/11 Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $15.00 price target on the stock, down previously from $16.00. -6.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: